The Blue Box Biomedical
1 known investors
The Blue Box Biomedical develops a urine-based breast cancer screening test that is pain-free and radiation-free, targeting women including those with dense breast tissue. The test reports a sensitivity of 88.42% and is intended for use in gynecology clinics, with clinical trials and launch planned for 2025-2026.
Investors · 1
Frequently asked questions
- What does The Blue Box Biomedical do?
- The Blue Box Biomedical develops a urine-based breast cancer screening test that is pain-free and radiation-free, targeting women including those with dense breast tissue. The test reports a sensitivity of 88.42% and is intended for use in gynecology clinics, with clinical trials and launch planned for 2025-2026.
- Who are The Blue Box Biomedical's investors?
- The Blue Box Biomedical's investors include WakeUp Capital.